Pharmacology of anistreplase.
Eminase (anistreplase), or anisoylated plasminogen streptokinase activator complex (APSAC), is a reversibly inactivated lys-plasminogen-streptokinase activator complex that is given rapidly over a period of 2-5 minutes, and has a half-life in the circulation of 90-105 min. Eminase represents a significant advance in drug design for therapeutic thrombolysis based on convenience in administration, high gradient (especially initially) for diffusion into thrombus, improved fibrin binding, ability to lyse fibrin rapidly, improved stability in the circulation, long duration of action, and production of an antithrombotic state.
Sherry
S
S
Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
D016255:Anistreplase; D004355:Drug Stability; D005343:Fibrinolytic Agents / Q000097:blood / Q000627:therapeutic use*; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D010958:Plasminogen / Q000378:metabolism / Q000627:therapeutic use*; D013300:Streptokinase / Q000378:metabolism / Q000627:therapeutic use*; D015912:Thrombolytic Therapy
D005343:Fibrinolytic Agents; D016255:Anistreplase; D010958:Plasminogen; D013300:Streptokinase